SigmaGraft Funding: How Much Did They Raise & Key Investors

How Much Did SigmaGraft Raise?
Funding & Key Investors

SigmaGraft, a California-based developer of biomaterials for dental and orthopedic applications, has secured significant capital, with total funding reaching $381K. The company recently announced a major strategic investment of $231K, underscoring its advanced stage of development and market traction in the competitive medtech sector. This latest financing round is expected to fuel further innovation and expansion of its product portfolio.

What is SigmaGraft?

SigmaGraft

Manufacturing

Medical Devices & Equipment

Pharmaceuticals

SigmaGraft Biomaterials specializes in creating advanced biomaterials designed to enhance patient outcomes in dental and orthopedic procedures. Their product line encompasses a range of solutions, including allografts, bone substitutes, resorbable membranes, and wound dressings. By fostering collaborations with leading clinicians and researchers, SigmaGraft aims to elevate the clinical experience and drive progress in regenerative medicine. The company's commitment to rigorous research and development positions it as a key player in the biomaterials industry.

How much funding has SigmaGraft raised?

SigmaGraft has raised a total of $381K across 2 funding rounds:

2020

Debt

$150K

2021

Debt

$231K

Debt (2020): $150K with participation from PPP

Debt (2021): $231K led by PPP

What's next for SigmaGraft?

The substantial backing indicated by $381K and the recent strategic investment of $231K suggest SigmaGraft is poised for significant growth and market penetration. This late-stage funding context implies a focus on scaling operations, expanding market reach, and potentially pursuing further product development or strategic acquisitions. The company's trajectory points towards solidifying its position as a leader in innovative biomaterial solutions for the healthcare industry.

See full SigmaGraft company page

See More Financial Insights